Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.

MLA

Caram, Megan E. V., et al. “Adherence and Out-of-Pocket Costs among Medicare Beneficiaries Who Are Prescribed Oral Targeted Therapies for Advanced Prostate Cancer.” Cancer, vol. 126, no. 23, Dec. 2020, pp. 5050–59. EBSCOhost, https://doi.org/10.1002/cncr.33176.

APA

Caram, M. E. V., Oerline, M. K., Dusetzina, S., Herrel, L. A., Modi, P. K., Kaufman, S. R., Skolarus, T. A., Hollenbeck, B. K., & Shahinian, V. (2020). Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer, 126(23), 5050–5059. https://doi.org/10.1002/cncr.33176

Chicago

Caram, Megan E V, Mary K Oerline, Stacie Dusetzina, Lindsey A Herrel, Parth K Modi, Samuel R Kaufman, Ted A Skolarus, Brent K Hollenbeck, and Vahakn Shahinian. 2020. “Adherence and Out-of-Pocket Costs among Medicare Beneficiaries Who Are Prescribed Oral Targeted Therapies for Advanced Prostate Cancer.” Cancer 126 (23): 5050–59. doi:10.1002/cncr.33176.